Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
A clear look at the stablecoins that outperformed peers this year, with insights into drivers and risk considerations for future allocations.
26,211 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Goldman Sachs trimmed its U.S. growth view as Iran-related tensions threaten more than higher oil prices. The shift s...
Fidelis Investors closes a $144 million RTL securitization, its third, backing 330 rehab loans across 29 lenders. The...
U.S. stocks rise as oil retreats and AI optimism fuels tech gains. This stock market live march edition tracks early ...
Joe Kent, a former Army Special Forces officer and two-time congressional candidate, quit today from a top counterter...
As Taysha prepares to share Q4 2025 results, investors search for clarity on cash runway, pipeline progress, and futu...
A veteran figure in AI, nicknamed the 'godfather ai,' argues big tech prioritizes short-term profits over the endgame...
Simone Biles and Jonathan Owens left their Texas custom home after a month, relocating to Indianapolis as Owens joins...
A bipartisan proposal aims to cap Social Security benefits for the wealthiest couples to address long-term solvency c...
Firms are tightening AI requirements across industries, pushing workers to upskill quickly. This article breaks down ...
Bitcoin sits at a regulatory crossroads as Consensus 2026 brings renewed debate over the Clarity Act. Hayes argues th...
A rapid Trump-backed rally has pushed stocks to fresh highs, yet selective bargains remain. The market shows pockets ...